<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285466</url>
  </required_header>
  <id_info>
    <org_study_id>CBEZ235A2118</org_study_id>
    <secondary_id>2010-022331-11</secondary_id>
    <nct_id>NCT01285466</nct_id>
  </id_info>
  <brief_title>A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab</brief_title>
  <official_title>A Phase Ib Multi-center, Open-label, 4-arm Dose-escalation Study of Oral BEZ235 and BKM120 in Combination With Weekly Paclitaxel in Patients With Advanced Solid Tumors and Weekly Paclitaxel/Trastuzumab in Patients With HER2+ Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of the trial is to determine the maximum tolerated dose (MTD) of BEZ235 and&#xD;
      BKM120 in combination with weekly paclitaxel and weekly paclitaxel/trastuzumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose limiting toxicities during the first cycle of treatment.</measure>
    <time_frame>First treatment cycle (4 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of safety events during the whole treatment period (until progression of disease).</measure>
    <time_frame>From start of treatment until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics of BEZ235, BKM120 and paclitaxel given in combination, on Day 1, 8 and 22.</measure>
    <time_frame>First treatment cycle (4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy (response to treatment according to RECIST criteria)</measure>
    <time_frame>From start of treatment until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of treatment on biomarkers of Pi3 Kinase pathway (analyses of skin biopsies, circulating markers)</measure>
    <time_frame>From start of treatment until disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Metastatic or Locally Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>BEZ235 + paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BKM120 + paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BEZ235 + paclitaxel + trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BKM120 + paclitaxel + trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEZ235 + paclitaxel</intervention_name>
    <arm_group_label>BEZ235 + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120 + paclitaxel</intervention_name>
    <arm_group_label>BKM120 + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEZ235 + paclitaxel + trastuzumab</intervention_name>
    <arm_group_label>BEZ235 + paclitaxel + trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120 + paclitaxel + trastuzumab</intervention_name>
    <arm_group_label>BKM120 + paclitaxel + trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with metastatic or locally advanced solid tumors, for whom weekly&#xD;
             paclitaxel treatment is indicated (BEZ235-paclitaxel /BKM120-paclitaxel treatment)&#xD;
&#xD;
          -  HER2+ metastatic or locally advanced breast cancer patients eligible for weekly&#xD;
             paclitaxel and trastuzumab (BEZ235-paclitaxel-trastuzumab&#xD;
             /BKM120-paclitaxel-trastuzumab treatment)&#xD;
&#xD;
          -  Adult patients (≥ 18 years) (males, females)&#xD;
&#xD;
          -  World Health Organization (WHO) performance status ≤ 2&#xD;
&#xD;
          -  Adequate bone marrow function:&#xD;
&#xD;
          -  Adequate hepatic and renal function:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with primary central nervous system (CNS) tumor or CNS tumor involvement.&#xD;
             However, patients with a metastatic CNS lesion may participate in this trial, if the&#xD;
             patient is &gt; 4 weeks from therapy (including radiation and/or surgery) completion,&#xD;
             clinically stable with respect to the tumor at the time of study entry, and not&#xD;
             receiving enzyme-inducing antiepileptic drugs or corticosteroid therapy or taper, as&#xD;
             treatment of the brain metastases&#xD;
&#xD;
          -  Patients who have received prior systemic anticancer therapy within the following time&#xD;
             frames&#xD;
&#xD;
          -  Cyclical chemotherapy: ≤ 3 weeks before study treatment (6 weeks for patients treated&#xD;
             with nitrosoureas)&#xD;
&#xD;
          -  Biological therapy: ≤ 4 weeks before study treatment, except treatment with&#xD;
             trastuzumab (both parts of the trial)&#xD;
&#xD;
          -  Investigational drug: ≤ 4 weeks before study treatment&#xD;
&#xD;
          -  Patients who have undergone major surgery ≤ 4 weeks before study treatment&#xD;
&#xD;
          -  Patients receiving chronic treatment with corticosteroids or other immunosuppressive&#xD;
             agents&#xD;
&#xD;
          -  Patients with uncontrolled, unmanageable, treatment-refractory diabetes mellitus&#xD;
&#xD;
          -  Active or history of major depressive episode, bipolar disorder, obsessive-compulsive&#xD;
             disorder, schizophrenia, history of suicide attempt or ideation, or homicide, as&#xD;
             judged by the investigator and/or based on recent psychiatric assessment&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14187</url>
    <description>Results for CBEZ235A2118 can be found on the Novartis Clinical Trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2011</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>BEZ235</keyword>
  <keyword>BKM120</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>trastuzumab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Dactolisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

